Nantahala Capital Management’s Tango Therapeutics TNGX Stock Holding History

Nantahala Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.7M	Sell	500,659 -749,793	-60%	-$18.5M	0.52%	51
2026 Q1	$26.2M	Sell	1,250,452 -2,322,181	-65%	-$32.3M	0.96%	24
2025 Q4	$31.7M	Buy	3,572,633 +1,762,685	+97%	+$15.2M	1.05%	21
2025 Q3	$15.2M	Sell	1,809,948 -1,629,646	-47%	-$11M	0.53%	46
2025 Q2	$17.6M	Buy	3,439,594 +451,611	+15%	+$1.12M	0.69%	32
2025 Q1	$4.09M	Buy	2,987,983 +183,573	+7%	+$451K	0.16%	80
2024 Q4	$8.67M	Buy	+2,804,410	New	+$13M	0.37%	51
2022 Q2	–	Sell	-98,794	Closed	-$749K	–	131
2022 Q1	$749K	Sell	98,794 -1,206	-1%	-$10.5K	0.03%	104
2021 Q4	$1.09M	Hold	100,000	–	–	0.04%	119
2021 Q3	$1.29M	Buy	+100,000	New	+$1.2M	0.04%	113
2021 Q2	–	Sell	-175,915	Closed	-$1.96M	–	131
2021 Q1	$1.96M	Sell	175,915 -24,085	-12%	-$277K	0.06%	100
2020 Q4	$2.29M	Hold	200,000	–	–	0.07%	99
2020 Q3	$2.07M	Buy	+200,000	New	+$2.04M	0.06%	97

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Nantahala Capital Management's TNGX Position: Q2 2026 in Review

Nantahala Capital Management reduced its Tango Therapeutics (TNGX) stake by 60% in Q2 2026, selling an estimated $18.5M and leaving 500,659 shares worth $15.7M. The position accounts for 0.52% of the portfolio, ranked #51.

Nantahala Capital Management first reported a position in TNGX in Q3 2020 and has held it in 13 quarters since. The position peaked at $31.7M in Q4 2025. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

Nantahala Capital Management held 500,659 shares of Tango Therapeutics worth $15.7M as of Q2 2026.
Nantahala Capital Management sold 749,793 Tango Therapeutics shares in Q2 2026, an estimated $18.5M.
Tango Therapeutics made up 0.52% of Nantahala Capital Management's portfolio in Q2 2026, its #51 holding.
Nantahala Capital Management first reported a position in Tango Therapeutics in Q3 2020 and has held it in 13 quarters since.
Nantahala Capital Management's Tango Therapeutics position peaked at $31.7M in Q4 2025.
248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.